Conclusion: In summary, CNTO3157 was ineffective in attenuating the effect of HRV-16 challenge on lung function, asthma control, and symptoms in asthmatic patients but suppressed cold symptoms in healthy subjects. Other approaches, including blockade of multiple pathways or antiviral agents, need to be sought for this high unmet medical need. (J Allergy Clin Immunol 2018;141:1220-30.)
Key words: Asthma, viral infection, inflammation, Toll-like receptor 3 Acute asthma exacerbations are episodes of worsening symptoms that can lead to augmentation of asthma therapy, hospitalization, and, on occasion, death. Asthma exacerbations are most often associated with respiratory viruses, with an estimated 65% to 85% of all viral exacerbations in children and 50% in adults being caused by human rhinovirus (HRV).
Although symptoms caused by HRV are usually restricted to the upper airways in nonasthmatic subjects, in asthmatic patients lower respiratory tract symptoms, including cough, dyspnea, and wheezing, are common. The mechanisms can include direct infection of the lower airway, 1,2 with worsening of inflammation caused by host defense mechanisms. The pathogenesis of HRV in the upper and lower airways has been extensively reviewed. 3 HRV infects a subset of cells in the respiratory epithelium, and viral replication initiates antiviral and proinflammatory responses through several molecular pathways.
Pattern recognition receptors that respond to HRV include several Toll-like receptors (TLRs), including TLR3, as well as the RNA helicases melanoma differentiation-associated gene 5 and retinoic acid-inducible gene I (RIG-I). 4 Inflammatory mediators released because of pattern recognition receptor signaling pathways include type I interferons (IFN-a/b), type III interferons (IFN-l1-4), IL-6, IL-12, and IL-15. 4, 5 Additionally, chemokines, including CXCL10/IFN-g-induced protein 10, 6 drive the recruitment of inflammatory cells, such as natural killer cells and type 1 lymphocytes.
Preclinical studies demonstrated that an anti-TLR3 mAb can block polyinosinic:polycytidylic acid (poly-I:C)-induced inflammation in vivo and in vitro 7 and can downregulate poly-I:C-induced production of inflammatory cytokines/chemokines (IL-6, IL-8/CXCL8, CCL2/macrophage chemoattractant protein 1, CCL5/RANTES, and CXCL10/IFN-g-induced protein 10 in human lung epithelial cells). 8 TLR3 antagonism also reduced mortality in an in-house mouse influenza model (unpublished data), which is consistent with published studies using TLR3-deficient mice. [9] [10] [11] We hypothesized that blockade of TLR3 signaling would attenuate the effect of HRV infection in asthmatic patients.
CNTO3157 is a fully human IgG 4k mAb that binds cell-surface TLR3, prevents association of double-stranded RNA with TLR3, and thereby inhibits TLR3 signaling-dependent generation of cytokines and other inflammatory mediators. Extensive published human in vitro and murine in vivo experiments supported the hypothesis that CNTO3157 would be an effective agent to suppress the inflammatory effects induced by rhinovirus infection (see Section E1 in this article's Online Repository at www.jacionline.org).
Here we present the effect of CNTO3157 compared with placebo on the respiratory manifestations of inoculation with HRV-16 in healthy subjects and patients with mild-to-moderate persistent asthma.
METHODS

Study design
This study was a 2-part, randomized, multicenter, double-blind, paralleldesign, placebo-controlled study to evaluate the efficacy and safety of CNTO3157 preceding inoculation with HRV-16. The study was approved by regional health authorities and ethics committees relevant for each investigational site. All participants demonstrated understanding of the study procedures and provided written consent before any study procedures. The full study protocol can be found in this article's Online Repository at www. jacionline.org.
Subjects
Nonsmoking healthy control subjects and patients with mild-to-moderate persistent asthma aged 18 to 65 years were recruited. Healthy control subjects were required to have no clinically significant abnormalities, as determined by medical history, physical examination, blood laboratory parameters, and electrocardiographic results.
Asthmatic patients had a physician's diagnosis of mild-to-moderate asthma for at least 6 months before screening, recently stable asthma based on a physician's assessment, an Asthma Control Questionnaire 7 (ACQ7) 12 symptom score of less than 1.5 (amended later in the study to <2.5), and a prebronchodilator FEV 1 of 65% of predicted value or greater. Low-to medium-dose inhaled corticosteroids (ICSs; based on the National Heart, Lung, and Blood Institute guidelines) 13 were permitted with additional controllers, excluding oral corticosteroids and biologic therapies. Subjects with prior lifethreatening asthma were excluded.
Subjects had a titer of serum neutralizing antibodies to HRV-16 of 2-fold dilution or less and previous serologic confirmation of prior infection with herpes simplex virus 1 (HSV-1) caused by associations of null TLR3 polymorphisms and childhood HSV-1 encephalitis. 14 
Randomization
Based on a computer-generated randomization schedule prepared before the study by an interactive voice or Web response system provider, healthy subjects in Part 1 were randomly assigned to 1 of 2 treatment groups in a 2:1 ratio (CNTO3157 vs placebo), and asthmatic patients in Part 2 were randomly assigned to 1 of 2 treatment groups in a 1:1 ratio (CNTO3157 vs placebo). The placebo used in the study consisted of the identical diluent used for CNTO3157 with no discernible visual differences, which was prepared on the day of administration by an independent person, such as a pharmacist, who was not part of the study team. 
Dose selection
The dosing regimen selected for CNTO3157 had been previously evaluated for safety and pharmacokinetic (PK) and pharmacodynamic (PD) effects in the first-in-human study in healthy volunteers who received ascending single doses of up to 10 mg/kg and in asthmatic patients who received 4 doses of up to 10 mg/kg CNTO3157 at weekly intervals (NCT01195207). More details can be found in Section E1.
Part 1: Healthy subjects
The principal objective of Part 1 was to evaluate the safety of CNTO3157, followed by nasal inoculation of HRV-16 in approximately 12 healthy adults.
Healthy subjects attended 2 screening visits to confirm eligibility and were then randomized on day 1 by using a 2:1 ratio to receive a single intravenous dose of CNTO3157 (10 mg/kg) or matching placebo, followed by inoculation of HRV-16 within 24 to 72 hours. Subjects attended the study unit daily for 5 days and at day 7 and day 10 after inoculation for study assessments and follow-up of adverse events (AEs). Additional follow-up visits occurred at approximately 4 and 8 weeks after randomization. Fig 1 presents a schematic of the study design for Part 1 (upper panel).
Part 1: Outcome measures
Outcome measures included safety, PK, and immunogenicity. The severity of the HRV-16-induced upper respiratory tract infection was assessed once daily by using a Cold Symptom Assessment Score (CSAS) based on a modified Jackson scale 15 and a combined Cold and Chest Symptom Scale (CCSS) score that was based on Jackson et al (questionnaire provided by SLJ). 16 Additional assessments included fraction of exhaled nitric oxide (FENO), spirometry, blood biomarkers, and nasal lavage for viral assessments.
Part 2: Patients with mild-to-moderate persistent asthma
The principal objective was to evaluate the efficacy of CNTO3157 for attenuating upper and lower respiratory manifestations after HRV-16 inoculation. We hypothesized that TLR3 blockade would attenuate the respiratory manifestations of HRV-16 in asthmatic patients.
Subjects attended up to 3 screening visits and were then randomly assigned by using a 1:1 allocation to intravenous CNTO3157 (10 mg/kg) or placebo on day 1, followed by 3 additional weekly doses of CNTO3157 (3 mg/kg intravenous) or placebo, followed by inoculation of HRV-16 within 24 to 72 hours of the last dose. Subjects attended the study unit daily for 5 days and then at days 7 and 10 after inoculation for study assessments, including spirometry. Additional followup visits occurred at approximately 7 and 11 weeks after randomization. Fig 1  (lower panel) presents a schematic of the study design for Part 2.
Part 2: Outcome measures
The primary end point was the maximum percentage decrease relative to preinoculation in all prebronchodilator FEV 1 measurements assessed at each visit from day 1 to day 10 after inoculation. Major secondary end points included area under the curve (AUC) for the CCSS score; CSAS score; morning peak expiratory flow rate (PEFR), and AUC prebronchodilator FEV 1 , all over the 10 days after inoculation; and the change from baseline in ACQ7 score at day 10 after inoculation.
Other end points include FENO value; Total Nasal and Ocular Symptom Score, which was assessed during the preinoculation treatment phase to assess any antiallergic benefit; nocturnal awakenings; and rescue medication use. Other assessments included the incidence of AEs, PK, and immunogenicity.
Biomarker assessments
Whole blood, serum, and nasal lavage samples and nasal brushings (Part 2 only) for biomarker analyses were collected and analyzed for the presence/ absence of HRV-16, HRV-16 titers, and other biomarkers. Biomarkers were assessed in nasal lavage fluid, blood, and sputum for proteomics (SomaLogics platform; SomaLogics, Boulder, Colo) and transcriptomics. A subset of subjects participated in sputum induction during screening and before and after inoculation with HRV-16. Detailed biomarker analyses can be found in Section E2 in this article's Online Repository at www.jacionline.org.
HRV challenge virus
The HRV-16 strain used was isolated through nasal lavage from a subject in a clinical study at the University of Virginia. Details about the origin of the virus appear in Section E3 in this article's Online Repository at www.jacionline.org. A confirmed infection with HRV-16 was defined as a positive culture from nasal lavage fluid at any time in the 5 days after inoculation and/or a 4-fold serologic conversion to HRV-16 assessed at the week 8 or 11 visits.
Safety
Safety was evaluated by assessment of AEs, clinical laboratory tests (hematology, serum chemistry, and urinalysis), vital signs, physical examinations, and electrocardiograms. Safety data obtained during the study were unblinded and reviewed on a routine basis by an independent data monitoring committee.
The safety analysis set included all subjects who received at least 1 dose of CNTO3157. If an event was judged by the investigator to be related to the study agent, investigators had the option of attributing AEs to active drug, placebo, or the HRV-16 inoculum.
Asthma exacerbations were defined a priori as ''severe'' or ''moderate.'' Severe exacerbations were defined as worsening of asthma requiring use of systemic corticosteroids, hospitalization, or both. Moderate exacerbations were defined as deterioration in lung function (> _30% decrease in the mean morning PEFR from baseline) lasting for 2 days or more and/or increased rescue bronchodilator use (> _3 additional puffs of rescue medication in 24 hours over the mean rescue medication use defined as the mean number of puffs taken during the 7 days before randomization).
Statistical analysis
Sample size calculation was based on the primary end point: the maximum percentage decrease relative to baseline in prebronchodilator FEV 1 measurements assessed at each visit through 10 days after inoculation with HRV-16. Based on Message et al, 17 60 subjects (30 per arm) were required for 80% power to detect a relative reduction in FEV 1 of 50% (from 13% decline for placebo to 6.5%) with an SD of 10% by using a 2-sided t test at a .1 level of significance. A .1 level of significance was selected because this was an early proof-of-concept study.
Demographic and baseline disease characteristic data were summarized by treatment group. Descriptive statistics were used to summarize continuous variables. Counts and percentages were used to summarize categorical variables. Categorical data were analyzed by using appropriate tests (x 2 tests, Cochran-Mantel-Haenszel x 2 tests, or logistic regression). Continuous responses were analyzed by using the same statistical method as in the primary efficacy analysis. Nonparametric methods were adopted when the normality assumption was violated. For efficacy analysis, data were analyzed according to the assigned treatment group. No corrections were made for multiple comparisons.
Primary efficacy analyses in Part 2 were based on a modified intention-totreat (mITT) HRV set including randomized subjects who received at least 1 (partial or complete) dose of CNTO3157 or placebo, had at least 1 efficacy measurement before HRV-16 inoculation, were inoculated with HRV-16, and had at least 1 postinoculation efficacy measurement during HRV-16 infection phase. The mITT set was defined as subjects who received at least 1 (partial or complete) dose of CNTO3157 or placebo, had at least 1 efficacy measurement before study agent infusion, and had at least 1 posttreatment efficacy measurement during the treatment phase.
Safety, PK, and PD analyses in parts 1 and 2 included all subjects treated with study agent and were summarized based on the actual treatment received. Some safety, PK, and PD analyses were performed on the population inoculated with HRV-16. In Part 1 healthy volunteers received 10 mg/kg CNTO3157 or placebo intravenously and were then inoculated with HRV-16 within 72 hours and monitored closely for 10 days after inoculation with safety follow-up visits at weeks 4 and 8. In Part 2 patients with mild-to-moderate persistent asthma received 10, 3, 3, and 3 mg/kg CNTO3157 or placebo intravenously at weekly intervals and were then inoculated with HRV-16 within 72 hours and monitored closely for 10 days after inoculation with safety follow-up visits at weeks 7 and 11.
The sponsor of the study, Janssen R&D (Spring House, Pa), wrote the protocol, and performed the analysis of the study. This article was written by Janssen and reviewed by all authors.
RESULTS Disposition
Part 1 was conducted at a single center in Belgium, whereas Part 2 was conducted at multiple sites in Canada, Denmark, Germany, Great Britain, and The Netherlands, from September 24, 2012, until November 17, 2014. The screen failure rate was high (approximately 93%; 771 subjects screened to randomize 63 subjects), driven primarily by serologic entry requirements (HRV-16 negative and HSV-1 positive). Fig 2 displays the disposition of subjects in the study who had a high completion rate.
Part 1: Healthy subjects
Thirteen healthy subjects were randomized into Part 1. Nine subjects received CNTO3157, and 4 received placebo; 1 subject receiving active therapy was not inoculated because of an AE of vomiting attributed to viral gastroenteritis. Baseline demographics were similar across the 2 treatment groups. All subjects were white, with a mean age of 53.6 years (range, 34-65 years), and were primarily (61.5%) male. All inoculated subjects receiving CNTO3157 and placebo had confirmed infection with HRV-16, as defined in the Methods section. No deaths, serious AEs, or other significant AEs occurred. The vast majority of AEs were mild in severity and self-limiting, and none were reported as related to CNTO3157. Seven subjects receiving CNTO3157 experienced at least 1 AE (77.8%) compared with 4 subjects (100%) receiving placebo.
There was significant inhibition (P 5 .03) of CSAS scores in subjects receiving CNTO3157 compared with placebo, with a mean AUC of the change from preinoculation through 10 days after inoculation of 9.1 (SD, 15.1) for the CNTO3157 group versus 34.9 (SD, 17.6) for the placebo group. Similarly, there was significant inhibition (P 5 .02) of CCSS scores in subjects receiving CNTO3157 compared with placebo, with a mean AUC of the change from before inoculation through 10 days after inoculation of 13.0 (SD, 18.4) for the CNTO3157 group versus 50.4 (SD, 25.9) for the placebo group, as depicted in Fig 3. Part 2: Asthmatic patients Demographic characteristics. The mean age of the asthmatic patients was 38.9 years (range, 18-65 years), and they were primarily (65.1%) male. Demographics and disease characteristics were generally similar between treatment groups. Sixty (95.2%) of the subjects were white. The asthma characteristics of randomized subjects are summarized in Table I . Overall, disease characteristics were similar across treatment groups, with no significant between-group differences. In general, asthma was mild in severity and well controlled on enrollment (mean ACQ7 score, <1.0). A higher proportion of subjects in the placebo group (70%) versus 58% of subjects receiving CNTO3157 reported ICS use at enrollment.
Disposition. Sixty-three asthmatic patients were randomized, of whom 61 received at least 1 dose of the study medication with 53 subjects completing all 4 doses. Thirty subjects receiving CNTO3157 and 25 subjects receiving placebo were inoculated with HRV-16. All 61 randomized subjects completed all scheduled visits. The proportion of confirmed infected subjects in the CNTO3157 group (24/30 [80.0%]) was significantly lower than in the placebo group (22/25 [88.0%], P 5 .031).
Primary end point. For the primary analysis set inoculated with HRV (mITT HRV), no significant difference (P 5 .60) was found between treatment groups for percentage change after Two prespecified sensitivity analyses were performed for the primary efficacy end point. Sensitivity analysis 1 included only those subjects who had all scheduled prebronchodilator FEV 1 measurements for 10 consecutive days after inoculation with HRV-16 (24/25 receiving placebo and 27/30 receiving CNTO3157). Sensitivity analysis 2 directly compared the treatment effect among those subjects in the mITT HRV analysis set (n 5 55) who were infected after inoculation with HRV-16 (22 receiving CNTO3157 and 24 receiving placebo). No significant differences were found between subgroups for sensitivity analyses 1 and 2 of the primary efficacy end point.
The following prespecified subgroups were analyzed by using baseline disease characteristics and concomitant asthma therapy (use of ICSs): There were no significant differences observed in any of the subgroup analyses that were conducted in regard to the primary end point. Fig 4 shows the percentage change in prebronchodilator FEV 1 from preinoculation baseline to 21 days after inoculation for the primary analysis set. The decrease in FEV 1 was approximately 50% of expected based on powering assumptions, as detailed in the Methods section.
Secondary end points. Major secondary analyses are presented in Table II . Both treatment groups showed worsening in all major secondary end points, with no significant difference between treatment with CNTO3157 or placebo. Except for the AUC over 10 days after inoculation for prebronchodilator FEV 1 , the changes were numerically greater in the CNTO3157 group but not to a clinically meaningful degree. Changes in CSAS and CCSS scores from preinoculation baseline are shown in Fig 5. After HRV-16 inoculation, both treatment groups showed acute increases in mean scores for both symptom scales, which peaked around day 3 after inoculation but resolved more quickly in the placebo group. CSAS and CCSS scores were numerically greater for those subjects receiving CNTO3157 compared with those receiving placebo.
There was a trend for improvement in Total Nasal and Ocular Symptom Scores (P 5 .07) for the CNTO3157 group compared with the placebo group at week 4. The CCSS score and CSAS were stable in both treatment groups during this phase. There were no significant between-group differences for demographics and disease characteristics. BMI, Body mass index.
FIG 4.
The primary end point: percentage change from preinoculation baseline in least squares mean (SE) prebronchodilator FEV 1 (mITT HRV-16 analysis set) for the CNTO3157 and placebo groups in Part 2 (patients with persistent asthma). There was no significant difference for maximal decrease or AUC day 1 to day 10 after inoculation between CNTO3157 and placebo.
inoculation. There were no significant or clinically meaningful differences for prebronchodilator FEV 1 between the CNTO3157 and placebo groups. The PK profiles of CNTO3157 in Parts 1 and 2 were similar to the profiles seen in the first-in-human study (NCT01195207) for similar doses and dosing regimens (data not shown). Only 1 subject in Part 2 had antidrug antibodies. See Section E4 in this article's Online Repository at www.jacionline.org for further details.
Safety
There were no serious AEs in Parts 1 or 2. In Part 2 five CNTO3157-treated subjects (17%) had asthma exacerbations after inoculation. Two of the 5 subjects had protocol-defined severe exacerbations (use of systemic steroids). The 2 severe exacerbations occurred on days 3 and 13 after inoculation, whereas the 3 moderate exacerbations occurred on day 2 and at weeks 7 and 11 after inoculation. All of the postinoculation asthma exacerbations occurred in subjects treated with CNTO3157. More detailed safety information is presented in Section E6 and Table E1 in this article's Online Repository at www.jacionline.org.
Viral load and infectivity
Viral load was not significantly different between the treatment groups (data not shown).
Biomarkers
During the treatment phase, FENO values were stable in both treatment groups, with no significant difference after the treatment phase compared with the pretreatment baseline (P 5 .91). FENO values showed slight increases in both treatment groups after inoculation compared with the pre-HRB16 inoculation baseline but returned to preinoculation levels during follow-up evaluations, with no significant difference between treatment groups (data not shown).
Nasal lavage
In Part 2 acute-phase proteins were significantly upregulated selectively in the CNTO3157 group. C-reactive protein levels were significantly increased with CNTO3157 compared with before inoculation on days 3 and 4 after inoculation and on day 4 after inoculation in the placebo group, with significantly higher increases in the CNTO3157 group compared with the placebo group. IL-6 levels were significantly increased in both treatment groups on days 3 and 4 after inoculation (see Fig E1 in this article's Online Repository at www.jacionline.org).
The interferon-induced chemokines CXCL10 and CXCL11 were upregulated in both the placebo and CNTO3157 groups in Part 2. Fig E2 in this article' s Online Repository at www. jacionline.org shows the AUC and maximal value for CXCL10 in Parts 1 and 2 after inoculation with HRV-16. For Part 1, there was a nonsignificant suppression of AUC CXCL10 (P 5 .19) and maximal CXCL10 (P 5 .58) in the CNTO3157 versus placebo group, whereas in Part 2 there was a trend for an increase in AUC CXCL10 (P 5 .08) and significant increase in maximal CXCL10 (P 5 .03) levels in the CNTO3157 group versus the placebo group. There was significant suppression of AUC and maximal CXCL10 levels (P 5 .01 and P 5 .01, respectively) for the placebo group in Part 2 (asthma) compared with Part 1 (healthy subjects), suggesting an intrinsic suppression of CXCL10 responses to viral inoculation in asthmatic patients that is not seen in the CNTO3157 group.
Of note, several type 2-associated analytes were modestly increased by HRV-16 in subjects receiving CNTO3157 but not those receiving placebo, including IgE, IL-5, and soluble IL-33 Values are presented as means (SDs). LS, Least square. From exploratory analyses of nasal lavage analytes measured by using the SomaLogic SOMAscan version 3 platform, all analytes significantly increased (false discovery rate < 0.05) at least 2-fold (day 4/baseline) in asthmatic patients after rhinovirus 16 infection in the CNTO3157 treatment group, and results in which such change was at least 2-fold (P <.05) that in the placebo group are reported in Table E2 in this article's Online Repository at www.jacionline.org. These results further support the observations that inflammation induced with rhinovirus 16 infection, including upregulation of acute-phase proteins, leukocyte chemoattractant chemokines, and neutrophil-and cytotoxic T cell-associated proteins, was further increased with CNTO3157 treatment relative to placebo.
No analytes were significantly modulated during the preinoculation treatment phase in either treatment group.
DISCUSSION
This is the first study evaluating an inhibitory anti-TLR3 mAb in asthmatic patients and the effects of this mAb on experimental viral challenge. Despite preclinical support for the concept, antagonism of TLR3 signaling was ineffective in attenuating the effects of HRV-16 infection on lung function or upper and lower airway symptoms in asthmatic patients.
CNTO3157 demonstrated slightly worse outcomes compared with placebo for both the primary and major secondary outcomes in asthmatic patients exposed to multiple weekly doses over 3 weeks. CNTO3157 also failed to reduce levels of nasal and serum CXCL10, a downstream marker for viral signaling. Finally, there were more moderate and severe asthma exacerbations reported in subjects receiving CNTO3157 compared with those receiving placebo after inoculation, which further suggests that CNTO3157 not only did not attenuate the manifestations of HRV-16 infection but might have made them slightly worse. In contrast, in healthy subjects there was some evidence to suggest that a single dose of CNTO3157 attenuated cold and chest symptoms, although in small numbers of subjects.
Typically, viral challenge results in a clinical cold with upper airway symptoms that peak at around 3 days after inoculation. In healthy subjects there are few to no chest symptoms, which is in contrast to asthmatic patients, in whom chest symptoms (eg, cough, wheeze, dyspnea, and phlegm production) are more commonly seen. Much more variable is the decrease in lung function after inoculation, which can be absent or only minimal in patients with mild and moderate asthma [18] [19] [20] in some reports but has been reported to be greater in patients with uncontrolled asthma with a lower FEV 1 . 21 Our assumptions for this study were that HRV-16 challenge would result in a decrease of 13% in prebronchodilator FEV 1 and that CNTO3157 would attenuate this decrease by 50% based on Message et al. 17 To increase the probability of seeing a moderate FEV 1 decrease, we allowed not only patients with mild but also those with moderate persistent asthma receiving ICS therapy and allowed subjects with a prebronchodilator FEV 1 as low as 65% of predicted value. Despite these criteria, the enrolled population was well controlled with preserved lung function, and this reduced the chance to demonstrate FEV 1 decrease (the maximal decrease for prebronchodilator FEV 1 on placebo was approximately 6%). Considering all efficacy end points and the excess of asthma exacerbations in the CNTO3157 group, these results provide compelling evidence that CNTO3157 compared with placebo was ineffective in attenuating and might have augmented the respiratory manifestations of HRV-16 in asthmatic patients.
Our primary hypothesis for the unsuccessful outcome of this study is that HRV-16 also interacted with other receptors, such as RIG-I and melanoma differentiation-associated gene 5, which were upregulated by the repeated dosing regimen in Part 2 and drove the increase in levels of CXCL10 and other acute-phase responses to HRV-16. 22, 23 Compatible with this notion is the significant increase in type 2 mediators (IgE, IL-5, sIL-33R) seen in the CNTO3157 group but not in the placebo group in Part 2. Of note, recent evidence suggests that stimulation of RIG-I increases type 2 inflammation through IL-33 production. 24 Second, blockade of TLR3, by reducing interferon signaling, could conceivably have left viral replication unchecked, resulting in worsening inflammation. This underpins a current theory attributing virus-induced asthma exacerbations to an acquired deficiency in interferon responses. 25, 26 However, we found no evidence for an increased nasal viral load in those who received CNTO3157. Finally, the dose of CNTO3157 was more than adequate for blockade of TLR3 based on a prior study, in which an ex vivo assay on whole blood stimulated with poly-I:C CNTO3157 administered the same regimen suppressed cytokine release, as described in the Methods section.
In keeping with our findings of increased type 2 inflammation, recent observations from a human model of HRV infection in asthmatic patients indicate a potential role of IL-33-dependent type 2 inflammation. Nasal lavage levels of IL-33, IL-4, IL-5, and IL-13 and bronchial lavage levels of IL-5 and IL-13 were significantly increased by HRV infection in patients with asthma and nasal and bronchial IL-33 correlated with clinical outcomes and viral load. 16 In another report a subset of asthmatic patients infected with HRV-16 (61%) had increased levels of secreted IL-25, a cytokine that can also augment type 2 inflammation in nasal mucosal fluid. 27 We observed a similar type 2-associated response to infection with HRV-16 in asthmatic patients, with the additional novel finding that antagonism of TLR3 appears to enhance the type 2 response, including levels of sIL-33R, relative to the placebo group. Our findings are consistent with those of previous reports indicating higher levels of sIL-33R in response to respiratory syncytial virus infection in infants 28 and might represent a protective host response mechanism similar to that described in models of allergic asthma 29 and LPS-induced acute lung injury in mice. 30 The HRV challenge model has been used for a number of years to study asthma pathogenesis and has been helpful in elucidating the mechanisms underlying virus-induced asthma exacerbations, as summarized in a recent review. 31 This challenge model has also been used extensively for common cold research. Based on our literature review, this study is one of the first to study an intervention with an mAb against TLR3 in asthma.
Significant disadvantages of this model include the need for subjects to have low titers against HRV, leading to a screen failure rate of approximately 50% for this reason alone; the need for parallel-group designs; the meager FEV 1 response in patients with well-controlled asthma; and the limited number of investigators available who are well versed in the conduct of this approach. The additional requirement for this study for subjects to be HSV-1 seropositive 14 contributed significantly to the screen failure rate, which was in excess of 90%. Despite these challenges, this study, in a modest number of subjects, provided a clear no-go for efficacy of CNTO3157 as an intervention to reduce asthma exacerbations.
Current approaches to reduction of asthma exacerbations include inhaled steroids and emerging anti-inflammatory agents, including anti-IgE, anti-IL-4 receptor, anti-IL-13, and anti-IL-5 mAbs. Despite these interventions, there is still significant unmet need with regard to the prevention of exacerbations, including in those who do not meet the type 2 inflammatory phenotype suitable for these mAb therapies, such as anti-IL-13 or anti-IL-5 mAbs. A diametrically opposite approach to blockade of TLR3, which inhibits the interferon axis, is the administration of nebulized interferon, which aims to boost antiviral host defense. This approach showed efficacy for ACQ, PEFR, and moderate asthma exacerbations in a post hoc analysis. 32 In this regard the ACQ score has been shown to be a strong predictor of future risk of exacerbations. 33 The limitations of this study include the milder than expected severity and good asthma control of the asthmatic participants, which might have reduced the chances of observing any benefit from TLR3 blockade. Enrollment of patients with mild controlled asthma was intentional because we were concerned about recruiting patients with more severe asthma and exposing them to an HRV-16 strain untested in asthmatic patients together with an anti-TLR3 antibody. The trends for worse outcomes in asthmatic patients receiving active drug compared with placebo and the imbalance in exacerbations supports our decision to focus on milder asthma for this study. Had the results of this study proved positive, we planned to study moderate-to-severe asthma in the next protocol. Second, although it is possible that the HRV-16 strain used was not as virulent as natural rhinovirus strains, in a prior study of this HRV-16 strain in healthy volunteers (NCT01466738), nasal symptom severity scores were comparable with those seen in patients with natural colds (personal communication, RBT), and therefore we believe this strain was virulent. The 5 asthma exacerbations reported after inoculation in Part 2 support this contention.
Finally, the effect of a single dose of CNTO3157 in the asthmatic cohort, as used in Part 1, the healthy control group in which symptoms were suppressed, might have led to a similar outcome in the asthmatic subjects in Part 2 by providing less time for induction of bypass proinflammatory pathways.
In summary, CNTO3157, a TLR3 antagonist mAb, was ineffective in attenuating the effect of an HRV-16 challenge on asthma control, asthma symptoms, and lung function. Other approaches, including blockade of multiple pathways and antiviral agents, need to be sought for this high unmet medical need.
